...
首页> 外文期刊>Cardiovascular and Interventional Radiology: A Journal of Imaging in Diagnosis and Treatment >Double Mesh Nitinol Stent Versus Self-expanding Stent-graft in Recurrent/Resistant Cephalic Vein Arch Stenoses in Dialysis Fistulae: A Comparative Study
【24h】

Double Mesh Nitinol Stent Versus Self-expanding Stent-graft in Recurrent/Resistant Cephalic Vein Arch Stenoses in Dialysis Fistulae: A Comparative Study

机译:双网状镍钛烯醇支架与复发/抗性头部静脉拱的自膨胀支架叶片在透析瘘中缩减:比较研究

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Purpose To compare the double mesh nitinol stent (DNS) versus the self-expanding stent-graft (SES) in recurrent/resistant cephalic vein arch stenosis in dialysis fistulae. Materials and Methods 17 cases with recurrent/resistant stenosis of the cephalic vein arch treated with a DNS were compared retrospectively with 18 cases treated with an SES. Stenting was performed either for significant recoil post-angioplasty with high-pressure balloons or in recurrent stenoses. Patients were followed up with Doppler ultrasound in our vascular access surveillance programme. Primary and assisted primary patency rates at 3, 6 and 12 months were estimated by Kaplan-Meier analysis. Results Both stents showed 100% technical success immediately post-stenting, defined as residual stenosis < 30%. 3, 6 and 12 month primary patency of the DNS was 82.4%, 69.7% and 28.1% versus 88.9%, 77.8% and 72.2% for the SES. The DNS had a mean primary patency of 242.4 days compared to 896.3 days for the SES (p = 0.021). 12 month assisted primary patency was 88.2% (DNS) and 100% (SES). The DNS had a mean assisted primary patency of 812 days compared to 1390.3 days for the SES, though this did not reach statistical significance. No stent fractures were identified at 2 years in either group. Conclusion Both stents had 100% technical success with no stent fractures. SES showed statistically significant higher primary patency. Assisted primary patency was also higher, though this did not reach statistical significance.
机译:目的比较双网状镍钛合金支架(DNS)与自膨式支架(SES)治疗透析瘘复发/难治性头静脉弓狭窄的疗效。材料与方法回顾性比较17例头静脉弓复发性/顽固性狭窄患者接受DNS治疗与18例接受SES治疗。在血管成形术后使用高压球囊或在复发性狭窄中进行支架植入,以获得显著的后坐力。在我们的血管通路监测项目中,对患者进行了多普勒超声随访。通过Kaplan-Meier分析估计3个月、6个月和12个月时的一期和辅助一期通畅率。结果两种支架术后即刻技术成功率均为100%,定义为残余狭窄<30%。3个月、6个月和12个月时,DNS的初级通畅率分别为82.4%、69.7%和28.1%,而SES的初级通畅率分别为88.9%、77.8%和72.2%。DNS的平均一次通畅期为242.4天,而SES为896.3天(p=0.021)。12个月辅助一期通畅率分别为88.2%(DNS)和100%(SES)。DNS的平均辅助初级通畅期为812天,而SES的平均辅助初级通畅期为1390.3天,尽管这没有达到统计学意义。两组均在2年内未发现支架骨折。结论两种支架均获得100%的技术成功,无支架断裂。SES显示出具有统计学意义的更高的原发性通畅率。辅助性一期通畅率也较高,但未达到统计学意义。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号